Literature DB >> 19476704

Effect of mobile phase pH and organic content on LC-MS analysis of nucleoside and nucleotide HIV reverse transcriptase inhibitors.

Zsuzsanna Kuklenyik1, Amy Martin, Chou-Pong Pau, J Gerardo Garcia-Lerma, Walid Heneine, James L Pirkle, John R Barr.   

Abstract

The HIV-1 reverse transcriptase inhibitors tenofovir (TFV), emtricitabine (FTC), and lamivudine (3TC) are widely used in the treatment of HIV-1-infected persons and are now being considered as chemoprophylactic drugs for the prevention of sexual HIV transmission. Assays that measure these drugs after either oral or topical application are critical to the understanding of the pharmacokinetic profiles of the drugs and allow a rational design of chemoprophylaxis modalities for evaluation in macaque models and human trials. We developed a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) method for sensitive measurement of FTC, 3TC, and TFV in plasma from macaques. To achieve detection limits of 10 pg on column, the plasma analytes were measured using acidic mobile phase and positive electrospray ionization MS-MS detection. However, this caused various chromatographic peak distortions, which were minimized by using mobile phase additives that induced ion-pairing interactions. Chromatographic peak tailing was minimized by adjusting the organic mobile phase concentration while considering the simultaneous effect of organic content on buffer and analyte pKa. Injection solution interferences were corrected by chromatographic peak focusing using column switching. The final method provides simultaneous measurement of all three analytes with a wide linear range of 1-3000 ng/mL using 0.1 mL plasma (10 pg on column) and coefficients of variation from 5% to 15% in the high ng/mL concentration range and from 16% to 20% in the low ng/mL concentration range.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19476704     DOI: 10.1093/chromsci/47.5.365

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  22 in total

1.  A Dose Ranging Pharmacokinetic Evaluation of IQP-0528 Released from Intravaginal Rings in Non-Human Primates.

Authors:  Jonathan T Su; Ryan S Teller; Priya Srinivasan; Jining Zhang; Amy Martin; Samuel Sung; James M Smith; Patrick F Kiser
Journal:  Pharm Res       Date:  2017-08-02       Impact factor: 4.200

2.  Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue.

Authors:  Charles Dobard; Sunita Sharma; Amy Martin; Chou-Pong Pau; Angela Holder; Zsuzsanna Kuklenyik; Jonathan Lipscomb; Debra L Hanson; James Smith; Francis J Novembre; J Gerardo García-Lerma; Walid Heneine
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings.

Authors:  Todd J Johnson; Priya Srinivasan; Theodore H Albright; Karen Watson-Buckheit; Lorna Rabe; Amy Martin; Chou-Pong Pau; R Michael Hendry; Ron Otten; Janet McNicholl; Robert Buckheit; James Smith; Patrick F Kiser
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

4.  Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis.

Authors:  Richard E Haaland; Amy Martin; Angela Holder; Jeffrey J Fountain; LaShonda Hall; Nicole A Pescatore; Sheila Heeke; Colleen F Kelley
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

5.  Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.

Authors:  James M Smith; Rachna Rastogi; Ryan S Teller; Priya Srinivasan; Pedro M M Mesquita; Umadevi Nagaraja; Janet M McNicholl; R Michael Hendry; Chuong T Dinh; Amy Martin; Betsy C Herold; Patrick F Kiser
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

6.  Pharmacokinetics and preliminary safety study of pod-intravaginal rings delivering antiretroviral combinations for HIV prophylaxis in a macaque model.

Authors:  John A Moss; Priya Srinivasan; Thomas J Smith; Irina Butkyavichene; Gilbert Lopez; Amanda A Brooks; Amy Martin; Chuong T Dinh; James M Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

7.  Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis.

Authors:  Priya Srinivasan; Jining Zhang; Amy Martin; Kristin Kelley; Janet M McNicholl; Robert W Buckheit; James M Smith; Anthony S Ham
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

8.  Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques.

Authors:  John A Moss; Amanda M Malone; Thomas J Smith; Irina Butkyavichene; Cassandra Cortez; Joshua Gilman; Sean Kennedy; Etana Kopin; Cali Nguyen; Preetha Sinha; R Michael Hendry; Patricia Guenthner; Angela Holder; Amy Martin; Janet McNicholl; James Mitchell; Chou-Pong Pau; Priya Srinivasan; James M Smith; Marc M Baum
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

9.  Effects of gel volume on pharmacokinetics for vaginal and rectal applications of combination DuoGel-IQB4012, a dual chamber-dual drug HIV microbicide gel, in pigtailed macaques.

Authors:  Lara E Pereira; Tyana Singletary; Amy Martin; Chuong T Dinh; Frank Deyounks; Angela Holder; Janet McNicholl; Karen W Buckheit; Robert W Buckheit; Anthony Ham; David F Katz; James M Smith
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

10.  Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine.

Authors:  Urvi M Parikh; Charles Dobard; Sunita Sharma; Mian-er Cong; Hongwei Jia; Amy Martin; Chou-Pong Pau; Debra L Hanson; Patricia Guenthner; James Smith; Ellen Kersh; J Gerardo Garcia-Lerma; Francis J Novembre; Ron Otten; Thomas Folks; Walid Heneine
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.